Clinical Trial Update: A Study of JAB-21822 in Adult Patients With Advanced Solid Tumors Harboring KRAS p.G12C Mutation in China [Phase 1, Phase 2]

View source ↗

Summary

Allist Pharmaceuticals is conducting a Phase 1/2 clinical trial of JAB-21822 in adults with advanced KRAS p.G12C-mutant solid tumors in China. The study include…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• JAB-21822

Snippet

Sponsor: Allist Pharmaceuticals, Inc. | Conditions: NSCLC, Solid Tumor | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING